RCT: Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes.

Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial – Nature Medicine

Related Study: Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial – Nature Medicine

Commentary: DAWN: Support for dorzagliatin–metformin combination therapy in type 2 diabetes – medwireNews

Commentary on Twitter

The DAWN study is a #phase3 clinical trial that demonstrates effective #glycemic control of #dorzagliatin as an add-on therapy to #metfomin in patients with type 2 #diabetes. #T2D #NMEDClinicalhttps://t.co/9bHWQNvNTJ

— Nature Medicine (@NatureMedicine) May 12, 2022